Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized evaluation of bortezomib plus R-CHOP for untreated diffuse large B-cell lymphoma
2010-022422-32Phase 3Unknown
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Nov 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2010-022422-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022422-32.